 All women will be informed about the trial and signed the informed consent documents, eligibility was determined based on medical history, and on general physical and gynecological examination. All women were informed by a physician of the risks and possible benefits of Hormone Replacement Therapy HRT. Upon inclusion, Transvaginal ultrasound TV-US was performed to evaluate the thickness of the endometrium at baseline. At study end-point, an endometrial biopsy will be performed with a Pipelle endometrial sampler to examine histological and immunohistochemical parameters . Vital signs, blood pressure, weight, Pap smear, mammography, routine clinical chemistry assays including, cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, triglycerides and hematology will also be evaluated at screening. 